Professor Peter Collins
Projects as PI
- A Multinational trial evaluating safety and efficacy, including PK of NNC when administered for the treatment and prophylaxis of bleeding in patients with Haemophilia A (21/12/2012 - 31/03/2018)
- A randomised multicentre, open label, phase 3 clinical trial to evaluate the efficacy, safety and PK of prophylactic RC5534262 versus no prophylaxis in haemophilia A patients with inhibitors (12/02/2016 - 31/03/2018)
- A randomised, multicentre, open-label, phase III clinical trial to evaluate the efficacy, safety and pharmacokinetics of prophylactic Emicizumab verse no prophylaxics in haemophilia A patients without inhibitors (05/10/2016 - 31/10/2018)
- Characterisation and role of phospholipids in the initiation of coagulation through tissue factor (01/08/2015 - 31/07/2018)
- Characterisation of platelet and microparticle phospholipids in thrombotic and bleeding disorders (01/08/2016 - 31/10/2019)
Projects as Co-Investigator
- Bioengineering of a dual-target therapeutic to modulate a pro-inflammatory and pro-coagulant pathology (01/02/2019 - 30/06/2021)
- Characterisation of novel endogenous lipid mediators of cardiovascular function and disease (20/05/2013 - 31/08/2018)
- Chemical biological and therapeutic actions of esterified eicosanoids generated by human immune cells: Understanding membrane signalling actions of novel lipid families (01/08/2011 - 31/12/2017)
- Clinical and cost-effectiveness of a maternity quality improvement
programme to reduce excess bleeding and need for transfusion after childbirth: the Obstetric Bleeding Study UK (OBS UK) Stepped Wedge Cluster Randomised Trial
(01/04/2023 - 31/12/2026) - Determining how bioactive phospholipids regulate development of abdominal aortic aneurysm and coagulation using multiomic approaches (17/03/2021 - 16/03/2026)